<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861493</url>
  </required_header>
  <id_info>
    <org_study_id>9221</org_study_id>
    <nct_id>NCT04861493</nct_id>
  </id_info>
  <brief_title>Cathelicidin LL-37 Levels in the GCF and the Saliva of Smokers and Non-smokers With Stage III,IV Periodontitis</brief_title>
  <official_title>Cathelicidin LL-37 Levels in the Gingival Crevicular Fluid and the Saliva of Smokers and Non-smokers With Stage III,IV Periodontitis :An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Periodontitis is considered an inflammatory disease that results in the disruption of oral&#xD;
      hemeostasis and is associated with the presence of dental plaque influenced by genetic and&#xD;
      environmental factors. It is well-establised that smokers have an increased severity of&#xD;
      periodontal disease,a higher prevalance of tooth loss and total edentulism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antimicrobial peptides (AMPs) are soluble molecules participating in the innate immunity of&#xD;
      mucosal surfaces against pathogens. Dysregulated expression of AMPs has been considered a&#xD;
      possible causal mechanistic link in the microbial dysbiosis associated with periodontal&#xD;
      disease and some risk factors, including tobacco smoking, diabetes mellitus, and&#xD;
      obesity.Antimicrobial peptides as a part of innate immunity are important molecules that&#xD;
      provide a balance between disease and health. Moreover, they are considered to be an&#xD;
      important intermediate step in initiating an initial immune response against the microbial&#xD;
      side of the gingival epithelium and in the transition to acquired immunity. Cathelicidins, in&#xD;
      particular - which play an important role in regulating the immunological response of oral&#xD;
      tissues, are a group of peptides released from neutrophil granules and they are present only&#xD;
      in humans in the form of LL-37.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">February 23, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>LL-37 levels in the GCF and saliva</measure>
    <time_frame>Through study completion,an average of 1 year</time_frame>
    <description>GCF,Saiva sampling to assess LL-37 levels by ELISA kit.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Smoking Reduction</condition>
  <arm_group>
    <arm_group_label>Smokers with stage III,IV periodontitis</arm_group_label>
    <description>patients with stage III,IV periodontitis having CAL&gt;5 mm and PD&gt;5 mm in one or more sites and bleeding on probing &gt;30% and smoking at least 10 cigarettes /day for a minmum of 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-smokers with stage III,IV periodontitis</arm_group_label>
    <description>patients with stage III,IV periodontitis having CAL&gt;5 mm and PD&gt;5 mm in one or more sites and bleeding on probing &gt;30% and they are never smoked before.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy patients</arm_group_label>
    <description>patients free from periodontitis or any systemic disease and never smoked before.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Gingival crevicular fluid samples Saliva samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1: Smokers with stage III,IV periodontitis Group 2: Non-smokers with stage III,IV&#xD;
        periodontitis Group 3: Healthy patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Presence of a minimum of 15 natural teeth.&#xD;
&#xD;
          2. At least four non-adjacent teeth sites in each jaw having CAL ≥ 5 mm and PD &gt; 5 mm in&#xD;
             one or more sites.&#xD;
&#xD;
          3. Bleeding on probing (BOP) ≥ 30%.&#xD;
&#xD;
          4. Tooth loss due to periodontitis ≤ 4 teeth.&#xD;
&#xD;
          5. For smoker's patients; study will include patients who regularly smoked at least 10&#xD;
             cigarettes/day for a minimum of 5 years.&#xD;
&#xD;
          6. For non-smokers patients; study will include patients who had never smoked.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals with a history of systemic diseases or immunological disorders.&#xD;
&#xD;
          2. Individuals using hormone replacement therapy.&#xD;
&#xD;
          3. Pregnant and lactating women.&#xD;
&#xD;
          4. Individuals that received periodontal treatment within the last 6 months.&#xD;
&#xD;
          5. Individuals with a history of systemic antibiotics and anti-inflammatory drugs within&#xD;
             the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ghallab</last_name>
    <role>Study Director</role>
    <affiliation>main supervisor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of dentistry cairo university</name>
      <address>
        <city>Al Manyal</city>
        <state>Cairo</state>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mai Magdy Abu El Eneen</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

